Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs CON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: ADUS 3 – 3 CON Matrix Metrics: ADUS 4 – 6 CON

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas CON carries 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin).

  • Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. CON 43.5/100 HOLD), CON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.2% vs. 10.4% operating margin) and revenue trajectory (+8.6% vs. +7.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs CON
ADUS NASDAQ
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66

6-Pillar Scorecard Institutional Category Breakdown (ADUS 3 – 3 CON)

Columns: Metric · ADUS · CON
1. Valuation Multiples ADUS
Forward P/E 16.1x 22.0x
Trailing P/E 20.1x 24.5x
PEG Ratio 1.05x N/M
EV / Revenue 1.5x 3.1x
2. Growth & Scale CON
Revenue Growth (YoY) +7.0% +8.6%
Earnings Growth (YoY) +24.2% +36.4%
TTM Revenue (USD) $1.50B $2.34B
Market Cap $2.3B $5.2B
3. Profitability & Quality CON
Gross Margin 32.3% 29.9%
Operating Margin 10.4% 17.2%
Net Profit Margin 7.4% 9.3%
Return on Equity (ROE) 10.0% 47.2%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $173M EBITDA $257M
Cash Flow Margin 11.5% EBITDA Mgn 11.0%
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $2.04B Net Debt (4.20x D/E)
Dividend Yield None (0.00%) 0.60%
5. Options & Positioning CON
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 21.9% (16th %ile) 269.9% (95th %ile)
Put/Call OI Skew N/A 0.79x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 21.9% of Rev ($329M) 12.7% of Rev ($297M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (4) vs CON (6)
Institutional Metric ADUS CON Criterion Row Edge
Market Capitalization
Scale
$2.3B $5.2B Larger Scale CON
Trailing P/E Ratio
Valuation
20.1x 24.5x Lower Multiple ADUS
Forward P/E Ratio
Valuation
16.1x 22.0x Lower Multiple ADUS
Revenue Growth (YoY)
Growth
+7.0% +8.6% Higher Growth CON
Operating Margin (TTM)
Profitability
10.4% 17.2% Higher Margin CON
Net Profit Margin
Profitability
7.4% 9.3% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
10.0% 47.2% Higher ROE CON
52-Week Range Position
Momentum
79% ($88–$132) 91% ($19–$44) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.52β · 38% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $2.34B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 29.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $257M ($2.04B Net Debt (4.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CON +4.82 pp
ADUS: -0.14% · CON: +4.68%
3M Horizon CON +18.19 pp
ADUS: +1.39% · CON: +19.58%
6M Horizon CON +33.02 pp
ADUS: +32.22% · CON: +65.24%
1Y Horizon CON +105.19 pp
ADUS: +12.39% · CON: +117.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs CON. Trailing 12-month operating profitability (ADUS 10.4% vs CON 17.2%) and valuation multiples (ADUS 16.1x vs CON 22.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
CON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.34B
Gross Margin29.9%
Op. Margin17.2%
ROE / Fwd P/E47.2% · 22.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs CON Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas CON carries 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin). Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. CON 43.5/100 HOLD), CON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.2% vs. 10.4% operating margin) and revenue trajectory (+8.6% vs. +7.0% YoY).

CON leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with CON at +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $2.34B for CON. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 12.7% of Rev ($297M) (0 disclosures) for CON.

ADUS screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus CON (47.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.